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ABSTRACT: The recombinant Kv7.2 calmodulin (CaM) binding site (Q2AB CaMBD) shows a high 
tendency to aggregate, thus complicating biochemical and structural studies. To facilitate these studies 
we have conceived bis-PEG-peptide CaMBD-mimetics linking helices A and B in single, easy to handle 
molecules. Short PEG chains were selected as spacers between the two peptide molecules, and a Cu(I)-
catalyzed cycloaddition (CuAAC) protocol was used to assembly the final bis-PEG-peptide conjugate, 
through the convenient functionalization of PEG arms with azide and alkyne groups. The resulting con-
jugates, with a certain helical character in TFE solutions (CD), showed nanomolar affinity in a fluores-
cence CaM binding in vitro assay, higher than just the sum of the precursor PEG-peptides affinities, thus 
validating our design. The approach to these first described examples of Kv7.2 CaMBD-mimetics could 
pave the way to chimeric conjugates merging helices A and B from different Kv7 subunits. 
 
Key words: PEG-peptide conjugates, Click chemistry, Calmodulin binding, Ion Channels, Fluores-
cence.  
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INTRODUCTION 
Kv7.2 and Kv7.3 subunits, encoded by the KCNQ2 and KCNQ3 genes, are the main components of 
the M-current, a voltage-dependent, non-inactivating K+ current that plays a critical role in controlling 
the activity of both peripheral and central neurons.1 
Like all Kv channels, the α subunits of the five members of the KCNQ family share a common core 
structure of six transmembrane segments with a voltage sensing domain (S1–S4) and a pore domain (S5 
and S6; see Figure 1).2 The large intracellular C-terminal tail contains four helical regions (A–D) crucial 
to channel assembly, gating and regulation, including the intercommunication with different regulatory 
factors. Discontinuous segments A and B¸ with high probability of adopting α–helix conformations, 
constitute the binding site for calmodulin (CaM),3 a ubiquitous calcium sensor which mediates traffic to 
the plasma membrane and Ca2+-dependent inhibition of Kv7 channels.4-6 Some spontaneous mutations 
located in helix A or B interfering with CaM binding, are linked to familial Benign Familial Neonatal 
Convulsions (BFNC),1 a dominantly inherited idiopathic human epilepsy. The “Benign” tag is mislead-
ing, because these mutations are often associated with poor outcomes.7, 8   
 
 
Figure 1. Topological representation of a Kv7.2 subunit and its calmodulin binding sites. Below are the 
partial sequences of helix A and B used in this paper. 
 
Although the knowledge about the Kv7-CaM interrelationship has advanced in recent years,9-11 fun-
damental aspects of the interaction are not known. Thus, a recent X-ray structure of the complex be-
tween CaM and the Kv7.4 helix B peptide has trapped Ca2+/CaM wrapping around the helix B in an 
antiparallel 1-14 binding-mode.12 However, this study only provides partial information about CaM 
binding to the Kv7 channels, since these channels have two CaM binding sites that are essential for the 
final binding mode of the complex.3, 13 For instance, it is expected that helices A and B interact with 
each other while binding to CaM,14 as described for other channels.15 In fact, we have found that CaM 
binds to either recombinant or synthetic helix A or B peptides, and the two sites cooperate to increase 
the affinity for this Ca2+ sensor.14 However, the long loop of 141 residues between helices A and B does 
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not seem to be directly involved in the interaction with CaM,3 although this linker regulates both surface 
expression and protein production.16  
The remarkable tendency of the recombinantly produced Kv7.2 CaM binding site (Q2AB CaMBD) to 
aggregate has precluded detailed biochemical and structural studies, and the chemical synthesis of the 
Q2AB CaMBD (> 100 amino acids) is impractical. An alternative to overcome these technical obstacles 
is to synthetize Q2AB CaMBD-mimetics that retain the fundamental properties regarding CaM-binding 
by joining A and B fragments in a unique molecule.  
Herein, we report the design and synthesis of two poliethyleneglycol PEG-peptide conjugates combin-
ing the amino acid sequence of helices A and B of Kv7.2. A 1,4-disubstituted 1,2,3-triazolyl scaffold 
was selected to join the two helical peptides in a single molecule (Figure 2). This heterocycle is easily 
accessible from alkyne and azide-substituted precursors using click chemistry, a well-recognized, pow-
erful tool in bioconjugation.17 As a first requirement for these conjugates to be further used as biological 
probes, we also report that the binding properties recapitulate those of the recombinant Q2AB CaMBD, 
and are not the result of the sum of the values of its precursors.   
 
Figure 2. Schematic representation of clicked peptide-conjugates derived from the amino acid sequence 
of Kv7.2. Linker: short PEG chains. 
 
RESULTS AND DISCUSSION 
 
Design of PEG-peptide conjugates. Peptides Ac-329FEKRRNPAAGLIQSAWRFYATN350-NH2 (de-
rived from Kv7.2 helix A) and Ac-508KVSIRAVCVMRFLVSKRKF526-NH2 (a fragment of Kv7.2 helix 
B) were selected based on the principles of consensus sequence reported.14, 18 A two point-mutation pep-
tide Ac-508KVSIRAVRVLRFLVSKRKF526-NH2, in which the native Cys
515 and Met517 residues of 
Kv7.2 are changed to Arg and Leu (as in Kv7.3 and Kv7.4), respectively, was also contemplated by 
technical reasons (see below). We hypothesized that the A and B helices adopt an antiparallel disposition 
upon CaM binding, as described in the structure of the related SK channel CaMBD/Ca2+/CaM com-
plex,15 and consequently the linkers to connect both molecules were incorporated at C- and N-terminal 
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positions, respectively (Figure 2). For this purpose, C-terminal Asn and N-terminal Lys functionalized 
side-chains were considered appropriate points for anchoring the spacer. 
Taking into account that solubility could be an issue for peptides longer than 6 residues, the linker 
could be selected to improve this property in the bis-A-B peptide conjugates in aqueous media. To this 
end, we envisaged the use of short poliethyleneglycol (PEG) units, a well-established strategy for pep-
tide modification that improves not only aqueous solubility, but also increases enzymatic stability and 
could reduce antigenicity and immunogenicity.19-21 Moreover, site-specific PEGylation of peptides was 
described to contribute to the stabilization of particular peptide secondary structures.22-24 To connect the 
PEG-peptides we opted for a 1,4-disubstituted 1,2,3-triazolyl ring, which could be built by Cu(I)-
catalyzed azide-alkyne cycloaddition, one of the most widely used Click chemistry reactions.17 This 
reaction is highly chemoselective, and can be performed in aqueous solution under mild conditions, be-
ing compatible with deprotected peptide side-chain functional groups.25-27 In fact, this 1,3-dipolar  cy-
cloaddition was already successfully applied to combine peptides and PEG-containing molecules, as in 
the synthesis of biodegradable peptide-based hydrogels and in the fluorescent labeling of nisin lantibiot-
ics, to cite two representative examples.28, 29  
To provide the conjugate molecule with certain flexibility upon CaM binding, a commercial 1-
aminotriethyleneglycol derivative, bearing an azido group at the end, was chosen to get the functionalize 
Asn350 residue of helix A (Figure 3). For helix B-derived peptides, a pent-4-ynoyl-substituted 1-
aminodiethyleneglycol-7-carboxyl moiety was attached in two steps to the Lys508 amino side-chain 
group. This led to final linkers of similar length on both peptides that, upon transformation into the tria-
zole-PEG-peptide conjugates, could force the motion of the two peptide arms in an antiparallel disposi-
tion. As the triazole ring can constitute a bend point, we preferred the indicated side-chain to side-chain 
location over placing it at the very N- or C-terminal positions, which could result in conjugates unable 
to bring close together the two peptides or that could align them in a wrong way. 
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Figure 3. Polyethyleneglycol linkers selected for the conjugation of peptides derived from Kv7.2 heli-
ces A and B sequences 
  
Synthesis. The synthesis of single peptide derivatives, Helix A329-350-PEG-azide (2), Alkyne-PEG-
Helix B508-526 (5) and its double mutant 6, were performed in parallel, following solid-phase protocols 
(Schemes 1 and 2). A low load Rink amide MBHA polystyrene resin (0.34 mmol g−1) was used to pre-
vent aggregation problems. Protecting groups are those normally used in an Fmoc/tBu strategy, and pep-
tides were elongated on the resin using HCTU as coupling agent. All compounds were isolated in high 
purity as C-terminal amides and acetylated at the N-terminal amino group. To allow the on-resin regi-
oselective functionalization of peptides, an Fmoc-Asp(OAll)-OH was incorporated as the first amino 
acid during the synthesis of resin bound peptide 1 (Scheme 1), while an Fmoc-Lys(Alloc)-OH was in-
troduced as the last residue in the sequence elongation to protected peptides 3 and 4 (Scheme 2). These 
All and Alloc groups can be orthogonally deprotected to facilitate the site-specific PEGylation at the 
Asp350 and Lys508 side-chains.30, 31 
Thus, after elongation to resin bound peptide 1, the Fmoc group was removed, the N-terminal NH2 
was acetylated, followed by the Pd-catalyzed deallylation of the C-terminal Asp residue side-chain. On 
resin coupling with a DMF solution of 11-azido-3,6,9-trioxaundecen-1-amine in the presence of HCTU 
afforded the corresponding Asn derivative, which upon acidic treatment led to cleavage from the resin, 
and concomitant side chain deprotection, to the expected Peptide-PEG-azide conjugate 2.   
Scheme 1. SPPS Synthesis of Helix A329-350-PEG-azide (2) 
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In a similar manner, resin-bound peptides 3 and 4, after N-terminal Fmoc-deprotection and acetyla-
tion, were treated with PhSiH3/Pd(PPh3)4 for Alloc group removal. Then, the free amino group of the 
Ac-Lys508 residue was reacted with a DMF solution of 2-[2-(Fmoc-amino)ethoxy]ethoxy]acetic ac-
id/HCTU (Scheme 2). After the PEGylation and Fmoc removal steps, a new coupling reaction was car-
ried out with 4-pentynoic acid/HCTU in order to incorporate the alkyne function. Finally, the obtained 
resins were treated with the cleavage cocktail TFA/EDT/H2O/TIS (94:2.5: 2.5:1) to afford the unbound, 
deprotected Alkyne-PEG-Helix B508-526 conjugates 5 and 6. 
 
Scheme 2. SPPS Synthesis of alkyne-PEG-Helix B508-526 
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Crude peptide-conjugates were precipitated from diethyl ether, centrifuged and lyophilized, and final-
ly purified by reverse phase MPLC using SPE cartridges or by semipreparative RP-HPLC-MS to obtain 
compounds 2, 5 and 6 in high purity (>98%, HPLC-MS data), which were characterize by ESI+ MS and 
HRMS. 
With Helix A329-350-PEG-azide conjugate 2 and alkyne-PEG-Helix B509-527 derivatives 5 and 6 in hand, 
we initiated the study of the Click reaction to combine them (Scheme 3). The conditions for the 1,3-
dipolar cycloaddition were initially studied for the reaction between compounds 2 and 6, this latter lack-
ing the Cys and Met residues of the native fragment, and therefore less prone to oxidation. We found 
that 1:1 mixtures of the corresponding azido- and alkyne-PEG-peptide derivatives in H2O/
tBuOH (2:1, 
rt, overnight), stirred in the presence of CuSO4.5H2O and sodium ascorbate,
32 led to the desired 1,4-
disubstituted 1,2,3-triazolyl containing bispeptide conjugates (Ac-329FEKRRNPAAGLIQS 
AWRFYATN350-NH2-PEG-triazole-PEG-Ac-
508KVSIRAVXaaVYaaRFLVSKRKF526-NH2; 7: Xaa = 
Cys, Yaa = Met; 8: Xaa = Arg, Yaa = Leu). Compounds 7 and 8 were obtained in high purity (>97%, 
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HPLC data, Figure 4) after purification of reaction crudes by reverse-phase semipreparative HPLC. 
Characterization of these peptide conjugates was performed by HPLC-MS and HRMS (EI+).  
Scheme 3. Synthesis of 329-350Helix A-PEG-triazole-PEG-Helix B508-526 conjugates 7 and 8 
 
 
 
10 
 
Figure 4. HPLC chromatograms of purified PEG-peptide conjugated 7 and 8 (C18 column, linear gradi-
ent from 5 to 80% ACN in 20 min). 
 
CD Studies. To evaluate the ability of mono- and bis-peptide conjugates to adopt helical structures, 
circular dichroism (CD) were performed (Figure 5 and S2). Most peptides showed no defined structure 
(random coil) in aqueous solution, and only compound 7 has a certain stabilization of the helix confor-
mation (Table 1). All of them become helical upon the addition of TFE (30%), as indicated by the char-
acteristic double minimum at 208 and 222 nm. The fact that these peptides turn into helix conformation 
in the presence of the structure-inducing cosolvent could be symptomatic of a tendency to be helical in a 
suitable environment (i.e., in the presence of CaM). As shown in Table 1, helix B-containing conjugates 
5 and 6 are highly helical (<90% helicity in TFE), while the helix character of the PEG-helix A peptide 
2 is smaller (24%). Bispeptide conjugates showed an intermediate situation, with mimetic 7 being clear-
ly more helical (35%) than analogue 8 (11%). While the C515R and M517L changes do not significant-
ly affect helicity of PEG-peptide 6 compared to native 5, these changes disturb in a greater extent the 
structuration of bis-PEG-peptide 8 related to 7. These results suggest an interrelation between the two 
helical segments in the bisconjugates that is disrupted by the indicated changes. 
Table 1. Experimental CD helicity (%) of peptide conjugates 
Compd. H2O 30% TFE 
2 2 24 
5 4 94 
6 3 91 
7 8 33 
8 1 11 
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Figure 5. CD spectra of peptides 7 and 8 in H2O and 30% TFE/H2O at pH 5.5 and 5 °C. 
 
CaM binding assays. To assess the ability to bind CaM, peptide conjugates 329-350Helix A-PEG-
triazole-PEG-Helix B508-526 7 and its C511R, M513L mutated analogue 8 were evaluated in a fluores-
cence CaM binding in vitro assay (emission spectra were recorded, as in Figure S3). As binding of pro-
teins to CaM sometimes relies on the C-lobe, others in the N-lobe, or the lobe-linker or combinations of 
those, it is impossible to know in advance if the position of the label is going to affect binding. To avoid 
this issue, the experiments were performed on three differently labeled CaMs. First, titration of unspe-
cifically dansylated CaM (D-CaM) with increasing concentrations of each peptide was carried out, both 
in the presence and the absence of a physiologically relevant concentration of free Ca2+ (Figure 6A, and 
S4). Then, we performed experiments on two different site-specific labeled CaMs (AEDANS-CaMs, 
carrying the point mutations T34C or T110C, respectively), having the AEDANS group on the CaM N 
or C lobe, respectively (Figure 5, B and C). Subsequently, we analyzed the data to obtain binding 
curves, from which binding parameters have been calculated (EC50, Hill coefficient, Tables 2 and S1; 
KD, Table S2). 
As shown in Figure 6, bis-PEG-peptide conjugate 7 is able to augment the fluorescent emission of the 
reporter CaM in a saturable dose-dependent manner, indicating a direct interaction of the conjugate with 
CaM. The position of the reporter fluorophore had little impact of the binding affinity (Table S1), sup-
porting the view that the obtained values are very close to the true affinity of unlabeled CaM.  The affin-
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ity, in the nanomolar range, is only two-fold lower than that previously determined for the recombinant 
A and B helices joined by the long 141 residues linker,14 and follows the same trend in the presence 
(lower affinity) and the absence of Ca2+ (higher affinity). Thus, compound 7 appears to be a reasonable 
mimetic for the Kv7.2 CaM binding site. Because the observed binding of bis-conjugate 7 could be ex-
plained trough the interaction of CaM with a single helix (A or B) or with both helices at a time, precur-
sors PEG-peptides 2 (helix A) and 5 (helix B) were also studied (Figure 7, and S5). In total agreement 
with previous results regarding recombinant or synthetic peptides derived from helix A or B,14 com-
pound 2 (helix A) showed greater increase in fluorescence than helix B-derived compound 5, but this 
latter displayed higher affinity (Tables 2 and S1). While the amplification of D-CaM fluorescent emis-
sion by PEG-peptide conjugate 2 was slightly lower than that of peptide pA (using the same assay), the 
apparent affinities were almost identical irrespective of the presence of Ca2+ or not. This indicates that 
the polyethyleneglycol has a negligible impact on binding to CaM. Compared to peptide pB, PEG-
conjugate 5 showed decreased apparent affinities, which could be due to either a negative influence of 
the PEG chain or to the differences in the sequence (lack of N-terminal GL residues, and/or detrimental 
effects of the C-terminal KRKF sequence). Both the maximal increase in fluorescence and the apparent 
affinity were greater for a 1:1 mixture of compounds 2 and 5 than for each peptide conjugate alone, in 
concordance with previous results for an equimolar mixture pA and pB.14 While interacting with CaM, 
the 2+5 mixture showed a lower increase of fluorescence and apparent affinities than the covalently 
connected bis-conjugate 7, suggesting a favorable role for the PEG linker in facilitating binding. 
Replacement of Cys
515
 and Met
517
 residues of helix B in 7 by Arg and Leu, respectively, led to bis-
conjugate 8, which decreases to approximately half the fluorescence and apparent affinity (i.e doubling 
the EC50) compared to 7 (Table 2, Figure S4). In the crystal structure of the Ca
2+
-CaM:Kv7.4 B-helix 
complex, this leucine was defined as a key interacting residue, occupying the main hydrophobic anchor-
ing pocket of the Ca
2+
-N-lobe
12
. As the Met by Leu change is conservative, it is expected that this Leu 
could contribute to the conjugate 8-CaM interaction in the same way than in above complex. However, 
the more drastic replacement of Cys by Arg is suggestive of an important role of Cys
515
 in the binding 
of Kv7.2 to CaM. The decreased helical stability of compound 8 in solution could also be related, at 
least in part, to the diminished affinity, requiring of higher energy to accommodate within the CaM–
peptide complex. 
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Figure 6. Dose-response interaction of peptide 7 (A-B) with fluorescently labeled CaMs. The sym-
bols indicate the total concentration of tagged-CaM used in each series. A) Relative concentration-
dependent enhancement of D-CaM fluorescence (blue) in the absence (left, filled symbols) and presence 
(middle, open symbols) of 3.9 µM free Ca
2+
. Right, extrapolation to the true affinity. Apparent dissocia-
tion constants (EC50) for the 7/CaM complex are shown as a function of the [CaM]. B) and C) Similar 
characterization using A34-CaM (red) or A110-CaM (green), respectively. Data represent the means ± 
S.E.M. from three or more independent experiments at each concentration of fluorescent labeled-CaM. 
The error bars are smaller than the symbols. The parameters used to fit a Hill equation to the data, using 
12.5 nM fluorescent CaM, can be found in Table 2 and S1. The Kd values can be found in Table S2. 
 
  
14 
 
Figure 7. The binding mode to peptide 7 is not the result of a linear interaction with its constituent 
peptides 2 and 5. A) Titration of 12.5 nM D-CaM fluorescence with peptide 2 (red), peptide 5 (blue) 
and an equimolar mixture of both (2 + 5, green). The black lines are the best fits to the data obtained for 
peptide 7. The experiments were performed in the absence (left, filled symbols) and presence (right, 
open symbols) of 3.9 µM free Ca2+. Data represent the means ± S.E.M. from three or more separate ex-
periments performed at each concentration of D-CaM. The error bars are smaller than the symbols. B) 
EC50 values obtained from binding curves were plotted versus [D-CaM] in order to extrapolate to the 
true affinities (Kd). The parameters used to fit a Hill equation to the data, using 12.5 nM fluorescent 
CaM, can be found in Table 2 and S1. The Kd values can be found in Table S2. 
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Table 2. Summary of the binding parameters obtained using 12.5 nM D-CaM. 
 
Peptide 
- Ca
2+
 (EGTA 10 mM) + Ca
2+
 (3.9 μM) 
Maximal fluo-
resc. increase 
 
EC50 (nM) 
 
h (n) 
Maximal fluo-
resc. increase 
 
EC50 (nM) 
 
h (n) 
7 (A-B) 84.3 ± 1.3 21.7 ± 1.1 1.7 ± 0.1 (4) 85.6 ± 0.7 40.5 ± 0.7 3.8 ± 0.2 (4) 
2 (A) 70.7 ± 1.6 42.7 ± 2.2 2.7 ± 0.3(4) 71.4 ± 1.2 69.8 ± 2.3 3.4 ± 0.2 (4) 
5 (B) 50.6 ± 1.2 29.1 ± 2.1 1.9 ± 0.3 (4) 53.4 ± 1.7 51.8 ± 3.7 2.8 ± 0.5 (4) 
2 + 5  81.8 ± 0.8 26.9 ± 0.7 2.7 ± 0.1 (4) 80.1 ± 1.5 47.3 ± 1.6 3.1 ± 0.3 (4) 
8 (A-B Mut) 44.6 ± 1.5 48.6 ± 3.6  2.7 ± 0.4  (3) 46.1 ± 0.7  88.6 ± 3.5  3.1 ± 0.3 (3) 
Q2AB
a,b
 111 ± 1.4 11.0 ± 0.5  1.6 ± 0.3   115 ± 2.1  27.1 ± 1.2  3.4 ± 0.5  
pA
a,c
 75 ± 3.9 42.9 ± 0.6  2.7 ± 0.6   96 ± 7.1 68.7 ± 9.7  1.7 ± 0.3  
pB
a,d
 35± 1.3 18.6 ± 1.8  2.0 ± 0.3   54 ± 1.5  43.1 ± 2.3  2.7 ± 0.3  
a Data from reference 14, using the same assay. b Q2AB (recombinant protein, Gly310-Leu548 region 
Kv7.2). c pA: 329FEKRRNPAAGLIQSAWRFYAT349. d pB: 504GLKVSIRAVCVMRFLVS522.  
 
 CONCLUSIONS 
We have designed and synthesized a bis-PEG-peptide conjugate, HelixA329-350-PEG-triazole-PEG-
HelixB508-526 (7), which merges in a molecule the Kv7.2 helices A and B, implicated in the intercommu-
nication with CaM. After SPPS of the corresponding azide-PEG- and alkyne-PEG-precursor peptides, 
both helices were combined through 1,2,3-triazole click chemistry. CaMBD-mimetic 7, composed of 42 
amino acid residues in total, is able to bind to CaM with high affinity, only two fold lower than that a 
recombinant protein containing both helices (239 residues). The affinity was virtually the same in spite 
of the fluorophore position in CaM, suggesting that the values obtained can be extrapolated to the true 
affinity for unlabeled CaM. This conjugate could be a useful biological probe to further investigate the 
association between CaM and Kv7.2 channel, and to better understand its regulation by Ca2+. Mutation 
of a couple of residues in helix B reduces the helical character of the bisconjugate and points to an im-
portant role of Cys515 residue in the binding of Kv7.2 to CaM. Finally, the synthetic approach described 
here could have application for the preparation of chimera conjugates, combining helices A and B from 
different Kv7 subunits, or, in a more general sense, for target sites conformed by dispersed segments 
within a protein.   
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EXPERIMENTAL PROCEDURES 
Materials. All reagents were of commercial quality. O-(6-Chlorobenzotriazol-1-yl)-N,N,N′,N′-
tetramethyluroniumhexafluorophosphate (HCTU), N,N-diisopropylethylamine (DIEA), 11-azido,3,6,9-
trioxaundecen-1-amine, 2-[2-(Fmoc-amino)ethoxy] ethoxy]acetic acid, 4-pentynoic acid, CuSO4.5H2O, 
sodium ascorbate, tetrakis(triphenylphosphine)palladium [Pd(PPh3)4], phenylsilane (PhSiH3), trifluoroa-
cetic acid (TFA), 1,2-ethanedithiol (EDT) and triisopropylsilane (TIPS), by SIGMA-ALDRICH. Anhy-
dride acetic (Ac2O) by Scharlau. N-Fluorenyl-9-methoxycarbonyl (Fmoc) protected L-amino acids 
(Fmoc-Thr(tBu)-OH, Fmoc-Ala-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Arg(Pbf)-OH, Fmoc-
Trp(Boc)-OH, Fmoc-Ser(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Gly-OH, 
Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Met-OH, Fmoc-
Cys(Trt)-OH, Fmoc-Lys(Alloc)-OH, Fmoc-Asp(OAll)-OH) and Rink amide MBHA resin LL (100-200 
mesh, loading 0.34 mmol/g) were provided by NOVABIOCHEM. N,N-dimethylformamide (DMF) and 
dichloromethane (DCM) were dried and purified by standard methods. 
General SPPS procedures for the synthesis of PEG-peptide conjugates. 
Coupling procedure. Rink amide MBHA resin (500 mg, 0.17 mmol) previously swollen in DMF and 
DCM (1ml/100mg of resin, 30 s x 4), was treated with 20% piperidine in DMF (1 x 5min) and (1 x 20 
min) and washed with DMF/DCM/DMF/DCM/DMF (4 x 0.5 min). In each coupling step, the appropri-
ate Fmoc amino acid (0.34 mmol, 2 equiv.) was treated with HCTU/DIEA (0.34 mmol, 2 equiv.) in dry 
DMF (1mL/100mg of resin) at room temperature for 1 h. The coupling efficiency was monitored by the 
ninhydrin test and, when necessary, repeated with a fresh portion of Fmoc-amino acid and the indicated 
coupling reagents.  
Acetylation method. The Fmoc-resin-bounded peptide, previously swollen, was treated with 20% piper-
idine in DMF (1 x 5 min) and (1 x 20 min) and washed with DMF/DCM/DMF/DCM/DMF (4 x 0.5 
min). Acetylation reactions were performed with DIEA (3.4 mmol) and Ac2O (3.4 mmol) in DMF for 1 
h and washed with DMF/DCM/DMF/DCM/DMF (4 x 0.5 min). 
Removal of Alloc and Allyl protecting groups. The resin bounded, fully protected peptide, previously 
swollen, was purged with Ar and treated with a solution of Pd(PPh3)4 (20 mg, 0.015 mmol) and PhSiH3 
(0.5 ml, 3.6 mmol) in anhydrous DCM (1 ml/100 mg of resin). The reaction mixture was stirred for 45 
min. This procedure was repeated once more time. The resin was washed with DCM/DMF/Et2NCS2Na 
(0.02M)/DMF/DCM (4 x 0.5 min). 
Cleavage step. Cleavage of peptides from the resin, and concomitant deprotection of side-chains, was 
performed using TFA/EDT/H2O/TIPS (94:2.5:2.5:1) (1 ml/100 mg of resin) at room temperature for 3 
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h. The resin was filtered off and crude products were precipitated with cold Et2O. The resulting solid 
was centrifuged and washed twice with ether, and then lyophilized.  
Peptide purification and characterization. Peptides were purified by MPLC using SNAP 12 g KP-C18-
HS cartridges in an ISOLERA ONE (BIOTAGE). A gradient of CH3CN:H2O (0.05% TFA) from 0:100 
to 30:70 over 60 min, as mobile phase, and a flow of 5 mL/min were used. Some peptides were purified 
by semipreparative RP-HPLC-MS (Waters 2545) coupled to a mass spectrometer 3100 detector, using a 
SUNFIRE
TM 
column C18 (5 µ, 10 x 150 mm) and an 8 mL/min flow with a gradient of CH3CN (0.1% 
HCO2H) [Solvent A]:H2O (0.1% HCO2H) [Solvent B] as mobile phase. The purity of peptides was ana-
lyzed using an analytical HPLC Waters (model 2690) with a SUNFIRE
TM 
column C18 (3.5 µ, 4.6 x 50 
mm, 1 mL/min) with a 5 min gradient of CH3CN (0.005% HCO2H) [Solvent A]:H2O (0.005% HCO2H) 
[Solvent B] as mobile phase, or  on Agilent apparatus (model 1120 Compact LC ) equipped with an 
Eclipse Plus column C18 (4.6 x 150 mm) at 1.5 mL/min flow, and passing a 5 to 80 gradient of CH3CN 
[Solvent A]:H2O (0.05% TFA) [Solvent B] as mobile phase, over 20 min. Characterization of the prod-
ucts was performed by simple ESI-MS (Waters, Micromass ZQ 2000) and HRMS (EI+, Agilent 6520 
Accurate-Mass Q-TOF LC/MS equipment). 
Ac-FEKRRNPAAGLIQSAWRFYATN(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-NH2 (2). Res-
in-bound peptide (500 mg, 0.17 mmol) 1, incorporating Asp(OAll) at C-terminal, was synthesized using 
general coupling procedure described above. After acetylation and OAll protecting group removal, a 
solution of 11-azido-3,6,9-trioxaundecen-1-amine (67.46 µL, 0.34 mmol), HCTU (141 mg, 0.34 mmol), 
DIEA (59 µL, 0.34 mmol) in 5 mL anhydrous DMF was added to the resin. After 2 h at room tempera-
ture, the excess of reagents were drained and the resin washed with DMF/DCM/DMF/DCM (5 x 0.5 
min) and checked by the Kaiser test. The peptide was cleaved as indicated above, and purified by 
MPLC to lead to 21 mg (5% total yield) of a white lyophilized solid with a purity of 99%. HPLC 
(Eclipse Plus column C18): tR = 10.25 min. ESI-MS: [M + 3H]
3+ 
= 947.48. HRMS (EI+) m/z 2837.4873 
([M]
+ 
C128H196N40O34, requires 2837.4838). 
Alkyne-PEG Peptides 5 and 6. Resin-bound peptides 3 and 4 (500 mg, 0.17 mmol), incorporating 
Fmoc-Lys(Alloc) at N-terminal, were synthesized using the general coupling procedure, followed by 
acetylation and Alloc protecting group removal, as described above. A solution of 2-[2-(Fmoc-
amino)ethoxy]ethoxy] acetic acid (131 mg, 0.34 mmol), HCTU (141 mg, 0.34 mmol), DIEA (59 µL, 
0.34 mmol) in 5 mL of anhydrous DMF was then added, and the reaction continued at room temperature 
for 2 h. After complete coupling, the resin was washed, drained and checked by the Kaiser test. The 
resin-bounded peptide was treated with 20% piperidine in DMF, to remove the Fmoc group on the ami-
no-PEG chain, washed rigorously with DMF/DCM/DMF/DCM (5 x 0.5 min) and treated with a solution 
of 4-pentynoic acid (34 mg, 0.34 mmol) in anhydrous DMF, HCTU (141 mg, 0.34 mmol) and DIEA (59 
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µL, 0.34 mmol) for 2 h at room temperature. The resin was washed with DMF/DCM/DMF/DCM (5 x 
0.5 min), drained and checked until the ninhydrin test was negative. The corresponding peptide was 
cleaved following the general procedure described above. 
Ac-K[2-(2-(Pent-4-ynamido)ethoxy)ethoxy)acetyl]VSIRAVCVMRFLVSKRKF-NH2 (5). Purifica-
tion by MPLC led to 44 mg (9% yield) of a white lyophilized solid with a purity of 98%. HPLC-MS 
(SUNFIRE
TM 
column C18): tR = 2.75 min with a 5 min gradient from 10 to 100 of CH3CN (0.08% 
HCO2H):H2O (0.01% HCO2H) as mobile phase. ESI-MS: [M + 5H]
5+ 
= 507.90. HRMS (EI+) m/z 
2532.4567 ([M]
+
C116H197N33O26S2, requires 2532.4549). 
Ac-K[2-(2-(Pent-4-ynamido)ethoxy)ethoxy)acetyl]VSIRAVRVLRFLVSKRKF-NH2 (6). Purifica-
tion by semipreparative RP-HPLC-MS with a gradient 2:98 to 40:60 (A:B) in 15 min. Yield (8 mg, 1%), 
white lyophilized solid with a purity of 99%. HPLC (SUNFIRE
TM 
column C18): tR = 2.72 min in 5 a min 
gradient 10:90 to 100:0 of (A:B) as mobile phase. ESI-MS: [M + 3H]
3+
 = 862.56. HRMS (EI+) m/z 
2582.6165 ([M]
+
C121H208N36O26, requires 2582.6139). 
Synthesis of peptide conjugates 7 and 8 by Click chemistry.   
General procedure for the Click reaction of alkyne- and azide-PEG-peptide derivatives. Alkyne pep-
tides 5 or 6 (4.22 µmol) were dissolved in H2O/
t
BuOH (2:1, 10 mL), and azide peptide 2 (4.22 µmol), 
CuSO4.5H2O (11 mg, 42.2 µmol), and sodium ascorbate (13 mg, 63.3 µmol) were added. The resulting 
mixtures were stirred at room temperature overnight, and QuadraSil
®
MP (85 µmol) was added, stirred 
for 10 min and filtered. The solutions were then concentrated and lyophilized. Crude products were pu-
rified by semipreparative RP-HPLC-MS to yield the corresponding 1,4-disubstituted 1,2,3-triazolyl-
PEG-peptides. 
1-[Ac-FEKRRNPAAGLIQSAWRFYATN(2-(2-(2-ethoxy)ethoxy)ethoxy)ethyl)-NH2]-4-[Ac-K(2-
(2-Propanamide)ethoxy)ethoxy)acetyl]VSIRAVCVMRFLVSKRKF-NH2]-1,2,3-triazole (7). Puri-
fied with a gradient from 2:98 to 30:70 (A:B) in 30 min. Yield (2 mg, 8%), white lyophilized solid with 
a purity of 98%. HPLC (Eclipse Plus column C18): tR = 9.86 min.  ESI-MS: [M + 5H]
5+
 = 1076.13, [M + 
6H]
6+
 = 899.23, [M + 7H]
7+
 = 768.81, [M + 8H]
8+ 
= 672.84. HRMS (EI+) m/z 5369.9375 
([M]
+
C244H393N73O60S2, requires 5369.9387). 
1-[Ac-FEKRRNPAAGLIQSAWRFYATN(2-(2-(2-ethoxy)ethoxy)ethoxy)ethyl)-NH2]-4-[Ac-K(2-
(2-Propanamide)ethoxy)ethoxy)acetyl]VSIRAVRVLRFLVSKRKF-NH2)-1,2,3-triazole (8). Puri-
fied with a gradient from 2:98 to 40:60 (A:B) in 15 min. Yield (1.4 mg, 6%), white lyophilized solid 
with a purity of 99% (total yield). HPLC (Eclipse Plus column C18): tR = 9.84 min. ESI-MS: [M + 
7H]
7+
= 773.85. [M + 8H]
8+
 = 677.58. [M + 9H]
9+
 = 602.08. [M + 10H]
10+
 = 541.91.  HRMS (EI+) m/z 
5419.0839 ([M]
+
C249H404N76O60 requires 5419.0898). 
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Proteins. Recombinant rat brain calmodulin (CaM) was produced in E.coli strain BL21-DE3 and puri-
fied as described.9 Dispersion of the samples was evaluated by dynamic light scattering (DLS) using a 
Zetasizer Nano instrument (Malvern Instruments Ltd.) in order to exclude the presence of aggregates. 
Fluorometry. Fluorescent dansylated CaM (D-CaM, 5-(dimethylamino)naphtalene-1-sulfonyl-
calmodulin) was prepared using recombinant CaM and dansyl chloride as described.33 CaM with a T to 
C mutation at threonine 34 or 110 and labeled with 5-((((2-iodoacetyl)amino)ethyl)-amino)naphthalene-
1-sulfonic acid (1,5-IAEDANS) to give A34-CaM and A110-CaM respectively, were kindly provided by 
Katalin Török (Division of Basic Medical Sciences, St George`s University of London, London, UK). 
Prior to the experiments, D-CaM and AEDANS-CaMs were dialyzed against 2 L of buffer containing 25 
mM Tris-HCl (pH 7.4), 120 mM KCl, 5 mM NaCl, 2 mM MgCl2 for 48 h, changing the buffer every 12 
h. Steady-state fluorescence measurements were performed with an Aminco Bowman series 2 (SLM 
Aminco) fluorescence spectrophotometer in a final volume of 100 μl (using quartz cuvette) at 25 °C. 
The excitation wavelength was 340 nm and emissions were recorded from 400 to 660 nm. Slit widths 
were set at 4 nm for excitation and 4 nm for emission. Peptides (0-800 nM) from a concentrated stock 
solution were incubated with D-CaM or the indicated AEDANS-CaM in 25 mM Tris-HCl (pH 7.4), 120 
mM KCl, 5 mM NaCl, 2 mM MgCl2, 10 mM EGTA or in the same buffer in the presence of calcium 
excess (by adding 9.63 mM Ca2+ to give a concentration of 3.9 µM free Ca2+). Free Ca2+ concentration 
was determined using Fura-2 (Invitrogen) following the manufacturer’s instructions. The concentration 
of D-CaM or AEDANS-CaMs (12.5-400 nM) was varied, and concentration-response curves were gen-
erated for fluorescence enhancement vs [ligand] to each D-CaM (or AEDANS-CaM) concentration. The 
parameters of the Hill equation (Fluorescence increase = A x [ligand]h / EC50 + [ligand]h; where A is the 
maximal fluorescence increase and h is the Hill coefficient) were fitted to the data by curvilinear regres-
sion, enabling the apparent affinity (EC50 or concentration that gives half-maximal change in fluores-
cence emission intensity) and Hill coefficient to be determined. EC50 values were plotted against the 
concentration of D-CaM (or AEDANS-CaM) to estimate the true affinities from the y axis intercept. 
Data are shown as average of three or more independent experiments. For all measurements, it has been 
subtracted the small contribution of the peptide signal because they emit at 425 nm after being excited, 
in solution, at 340 nm. 
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-PEG-triazole-PEG-HelixB
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 (41 residues), prepared through 
click chemistry of PEGylated peptide derivatives, bind to CaM with nanomolar affinity, behaving 
as mimics of the Kv7.2 native fragment (239 residues). 
 
